A Retrospective Analysis of the Efficacy and Safety of Imatinib for Advanced Gastrointestinal Stromal Tumor in Elderly Patients.

ABSTRACT:

Background

Gastrointestinal stromal tumor (GIST) occurs predominantly in the elderly population. However, clinical data on the outcomes of treatment with imatinib in elderly patients are limited. The aim of this study was to determine the efficacy and safety of imatinib for advanced GIST in the elderly population compared with the non-elderly population.

Methods

We analyzed the clinical data of patients who received imatinib as first-line treatment for advanced GIST at our hospital between January 2010 and July 2023. Progression-free survival (PFS), overall survival (OS), and adverse events were compared between elderly patients (age ≥ 70 years, E group) and non-elderly patients (age < 70 years, NE group).

Result

Data of 91 patients (E group, n = 32; NE group, n = 59)

SUBMITTER: Awatsu T 

PROVIDER: S-EPMC12576807 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature